Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets  by Chirkov, Yuliy Y et al.
Stable Angina and Acute Coronary Syndromes Are
Associated With Nitric Oxide Resistance in Platelets
Yuliy Y. Chirkov, PHD, Andrew S. Holmes, BSC, HONS, Scott R. Willoughby, PHD, Simon Stewart, PHD,
Ronald D. Wuttke, BSC, Peter R. Sage, MBBS, John D. Horowitz, PHD
Adelaide, Australia
OBJECTIVES The study examined possible clinical determinants of platelet resistance to nitric oxide (NO)
donors in patients with stable angina pectoris (SAP) and acute coronary syndromes (ACS),
relative to nonischemic patients and normal subjects.
BACKGROUND We have shown previously that platelets from patients with SAP are resistant to the
antiaggregating effects of nitroglycerin (NTG) and sodium nitroprusside (SNP).
METHODS Extent of adenosine diphosphate (1 mmol/liter)-induced platelet aggregation (impedance
aggregometry in whole blood) and inhibition of aggregation by NTG (100 mmol/liter) and
SNP (10 mmol/liter) were compared in normal subjects (n 5 43), nonischemic patients (those
with chest pain but no fixed coronary disease, (n 5 35) and patients with SAP (n 5 82) or
ACS (n 5 153). Association of NO resistance with coronary risk factors, coronary artery
disease (CAD), intensity of angina and current medication was examined by univariate and
multivariate analyses.
RESULTS In patients with SAP and ACS as distinct from nonischemic patients and normal subjects,
platelet aggregability was increased (both p , 0.01), and inhibition of aggregation by NTG
and SNP was decreased (both p , 0.01). Multivariate analysis revealed that NO resistance
occurred significantly more frequently with ACS than with SAP (odds ratio [OR] 2.3:1), and
was less common among patients treated with perhexiline (OR 0.3:1) or statins (OR 0.45:1).
Therapy with other antianginal drugs, extent of CAD, intensity of angina and coronary risk
factors were not associated with variability in platelet responsiveness to NO donor.
CONCLUSIONS Patients with symptomatic ischemic heart disease, especially ACS, exhibit increased platelet
aggregability and decreased platelet responsiveness to the antiaggregatory effects of NO
donors. The extent of NO resistance in platelets is not correlated with coronary risk factors.
Pharmacotherapy with perhexiline and/or statins may improve platelet responsiveness to NO.
(J Am Coll Cardiol 2001;37:1851–7) © 2001 by the American College of Cardiology
“Endothelial dysfunction” has been proposed not only as a
fundamental component of the pathophysiology of most
coronary risk factors (diabetes, hypercholesterolemia, sys-
temic hypertension, smoking), but also as playing a part in
homeostatic disturbances associated with ischemic heart
disease. Classically, endothelial dysfunction has been de-
fined as impaired/absent vasodilator response to agents
inducing release of nitric oxide (NO) from vascular endo-
thelium, in the presence of “intact” response to exogenous
NO from organic nitrates such as nitroglycerin (NTG)
(1–3). However, evidence is accumulating that this concept
is inaccurate in a number of important ways. First, respon-
siveness to various agents releasing NO from endothelium
may be heterogeneously impaired—for example, with dif-
ferential impairment of response to acetylcholine versus
bradykinin (4). More importantly, a large number of studies
now demonstrate that “endothelial dysfunction,” as classi-
cally defined, is in fact associated with marked impairment
of response to NO donors in both peripheral (5) and
coronary (6) vessels. This has led to the suggestion that the
phenomenon be redesignated vasodilator dysfunction (7);
the prognostic implications of this anomaly within the
coronary vascular bed have been examined, and it has been
shown that coronary vasodilator dysfunction is an indepen-
dent predictor of adverse cardiovascular events.
Hyporesponsiveness of target tissues to the effects of NO
(endogenous or exogenous) may, however, extend beyond
vascular smooth muscle and include platelets (8–10). In
platelets, the antiaggregatory effects of NTG and other
nitrovasodilators are also mediated by the formation of NO,
which activates platelet guanylate cyclase, leading to gener-
ation of cyclic guanosine-39,59-monophosphate (cGMP)
(for review see Reference 11). The examination of NO
responsiveness in platelets offers a convenient and reliable
means for evaluating differences between and within patient
populations, with comparison to normal subjects. Previous
investigations have demonstrated resistance to the antiag-
gregatory effects of NO donors on platelets in the presence
of hypertension (12) and diabetes/obesity (13,14). We have
also documented a similar phenomenon in patients with
stable angina pectoris (SAP) (10,15), in whom oxidative
stress appears to induce increased clearance of NO by
superoxide anion radical (O2
2) and inactivation of soluble
guanylate cyclase (16). Oxidative stress may vary with
extent of myocardial ischemia, coronary risk factors and
some forms of pharmacotherapy, such as antioxidants,
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angiotensin-converting enzyme (ACE) inhibitors and lipid-
lowering agents (for review see Reference 17).
Given the pathophysiological role of incremental oxida-
tive stress in NO resistance, the current study was under-
taken to investigate whether the extent of the platelet NO
resistance in patients presenting with chest pain: 1) depends
on the underlying diagnosis (nonischemic chest pain, SAP
or acute coronary syndromes [ACS]) and extent of fixed
coronary artery disease, and 2) is associated with coronary
risk factors and pharmacotherapy. The inhibitory effects of
NTG and sodium nitroprusside (SNP) on adenosine
diphosphate (ADP)-induced platelet aggregation were ex-
amined in blood samples obtained from normal subjects,
nonischemic patients with normal coronary arteries, patients
with stable angina and patients with ACS in order to
identify potential clinical correlates of NO resistance at the
level of platelet aggregation.
METHODS
Patients/normal subjects. Patient characteristics are
shown in Table 1. Patients with SAP (aged 39 to 76 years,
n 5 82) were evaluated at the time of diagnostic cardiac
catheterization and coronary angiography. In all cases at
least one hemodynamically significant ($50%) stenosis was
present in a major coronary artery. Patients with ACS (aged
37 to 98 years, n 5 153) were admitted for treatment of
prolonged chest pain occurring at rest and were studied
during the first hour after admission; eventual diagnosis was
unstable angina pectoris (n 5 100) or non-Q-wave myo-
cardial infarction (n 5 53). Nonischemic patients (aged 35
to 77 years, n 5 35) presented with chest pain but were
found to have angiographically normal coronary arteries at
diagnostic cardiac catheterization. In all patients a back-
ground medication profile was recorded at recruitment. No
patient was receiving ADP receptor or glycoprotein IIb/IIIa
receptor antagonists. A cohort of healthy volunteers (n 5
43; 23 men and 20 women aged 23 to 76 years, mean 46
years) not taking any medication affecting platelet aggrega-
tion was also studied. In all cases, blood samples were
collected for assessment of platelet aggregation. The isch-
emic patients were compared with nonischemic patients,
who were of similar ages, and with apparently healthy
volunteers. Numbers of subjects utilized in individual ex-
periments are indicated in the Results section. The protocol
was approved by the Ethics of Research Committee of The
Queen Elizabeth Hospital; informed consent was obtained
prior to study entry.
Blood sampling and platelet aggregation studies. Blood
samples from patients undergoing cardiac catheterization
were collected during the procedure via a femoral arterial
sheath, and from other patients and normal volunteers by
venesection from an antecubital vein. We have shown
previously (10) that there is no arteriovenous difference in
platelet function. Blood was collected in plastic tubes
containing 1:10 volume of acid citrate anticoagulant (two
parts of 0.1 mol/liter citric acid to three parts of 0.1 mol/liter
trisodium citrate); acidified citrate was utilized to minimize
deterioration of platelet function during experiments (18).
Aggregation in whole blood was examined utilizing a
dual-channel impedance aggregometer (Model 560,
Chrono-Log, Haverstown, Pennsylvania) as described pre-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ACS 5 acute coronary syndromes
ADP 5 adenosine diphosphate
ANOVA 5 analysis of variance
cGMP 5 cyclic guanosine-39,59-monophosphate
NO 5 nitric oxide
NTG 5 nitroglycerin
OR 5 odds ratio
SAP 5 stable angina pectoris
SNP 5 sodium nitroprusside
Table 1. Patient Characteristics
Characteristic
NIP
(n 5 35)
SAP
(n 5 82)
ACS
(n 5 153)
Men/women, n 17/18 57/25 95/58
Age (mean 6 SD), yrs 54 6 12 64 6 10 67 6 10
Diabetes, n (%) 1 (3) 25 (30) 40 (26)
Hypertension, n (%) 9 (25) 43 (52) 83 (54)
Hypercholesterolemia, n (%) 5 (14) 42 (51) 73 (48)
Smoking, n (%) 5 (14) 10 (12) 34 (22)
Drugs used
Aspirin, n (%) 10 (29) 69 (84) 111 (73)
Nitrates, n (%) 6 (17) 47 (57) 112 (73)
ACE inhibitors, n (%) 4 (11) 21 (26) 35 (23)
SH-donors (e.g., N-AC), n (%) 0 (0) 10 (12) 30 (20)
Perhexiline, n (%) 1 (3) 12 (15) 19 (12)
Statins, n (%) 5 (14) 29 (35) 41 (27)
Ca21-antagonists, n (%) 14 (40) 48 (59) 90 (59)
Beta-adrenoceptor antagonists, n (%) 2 (6) 20 (24) 25 (16)
ACE 5 angiotensin-converting enzyme; ACS 5 acute coronary syndromes; N-AC 5 N-acetylcysteine; NIP 5 nonischemic
patients; SAP 5 stable angina pectoris; SH 5 sulphydryl.
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viously (16). In brief, tests were performed at 37°C and
stirring speed of 900 rpm. Samples of blood were diluted
twofold with normal saline (final volume 1 ml) and pre-
warmed for 5 min at 37°C. Aggregation was induced with
ADP (final concentration of 1 mmol/liter). Aggregation was
monitored continually for 7 min, and responses were re-
corded for electrical impedance in ohms. Both SNP and
NTG (final concentration of 10 and 100 mmol/liter, respec-
tively) were added to samples 1 min before ADP. Duration
of the incubation was estimated as the optimal in prelimi-
nary experiments (data not shown). In control tests, physi-
ological saline was added in appropriate volumes. Inhibition
of aggregation was evaluated as a percentage comparing the
extent of maximal aggregation in the presence and absence
of the antiaggregatory agent studied. Representative aggre-
gograms for a normal male subject are shown in Figure 1.
Chemicals. Adenosine 59-diphosphate sodium salt and
SNP were obtained from Sigma (St. Louis, Missouri).
Nitroglycerin was purchased from Fisons (Thornleigh, New
South Wales, Australia).
Data analysis. CATEGORIZATION OF CORONARY RISK FAC-
TORS. Plasma cholesterol level .5 mmol/liter was consid-
ered as a risk factor. Cigarette smokers were defined as
subjects who were current smokers. Diabetes mellitus was
diagnosed according to the criteria of the World Health
Organization. Hypertension was defined as previous docu-
mentation of systolic blood pressure $140 mm Hg or
diastolic blood pressure $90 mm Hg. Male gender was
considered as a risk factor and, therefore, all comparisons of
platelet ADP responses were stratified according to subject
gender. Advanced age ($70 years) was also treated as a
potential risk factor.
STATISTICS. Comparisons of platelet responses between
normal subjects and different groups of patients were made
utilizing analysis of variance (ANOVA) followed by the
two-sided Dunnett test (for multiple comparisons) or the
Student nonpaired t test as appropriate. Univariate analysis
of the effects of each potential coronary risk factor and
therapy on NO responsiveness was performed with one-way
ANOVA for categorical variables. Possible interactions
among risk factors, therapies and platelet responsiveness to
SNP and NTG were examined by stepwise multiple regres-
sion analysis (multivariate analysis). For the purpose of this
analysis, NO resistance was categorized as hyporesponsive-
ness of platelets to SNP to an extent of 2 SD below the
mean response documented in normal subjects. Statistically
significant difference was limited to p , 0.05. Results are
expressed as mean 6 SEM unless otherwise stated.
RESULTS
Patient characteristics. Characteristics of the SAP (n 5
82), ACS (n 5 153) and nonischemic patient (n 5 35)
groups are summarized in Table 1. Of the coronary risk
factors examined (male gender, age .70 years, diabetes
mellitus, systemic hypertension, hypercholesterolemia and
smoking), the mean number of risk factors was 2.71 6 0.99
(SD) in the SAP group and 2.78 6 0.89 (SD) in the ACS
group. Almost all patients with either SAP or ACS were on
multiple drug therapy. Numbers of cases sufficient for
multivariate analysis were present in respect to therapy with
aspirin, nitrates, sulphydryl donors (N-acetylcysteine or
captopril), ACE inhibitors, HMG-CoA reductase inhibi-
tors (“statins”), Ca11-antagonists, beta-adrenoceptor an-
tagonists and perhexiline for both SAP and ACS groups.
The group of nonischemic patients differed considerably
from SAP or ACS groups regarding age, numbers of
coronary risk factors and extent of pharmacotherapy.
ADP-induced platelet aggregation. We examined platelet
responsiveness to ADP in blood samples obtained from
normal subjects, nonischemic patients with normal coronary
arteries, patients with SAP and with ACS. Platelet aggre-
gation studies usually exclude individuals taking aspirin
because of the suppression of thromboxane A2 generation
by aspirin. However, as the majority of patients with
ischemic heart disease normally receive aspirin, we included
such patients in the current study. We used a relatively low
concentration of ADP, 1 mmol/liter, which does not cause
a release of thromboxane A2 (18). In accordance with our
previous study (16), no statistically significant differences
were seen in platelet responses to this concentration of ADP
between patients receiving and not receiving aspirin (data
not shown). Therefore, data from these patient groups were
pooled; results are summarized in Table 2. Platelet aggre-
gability in response to ADP was greater in women than in
men (ANOVA: p , 0.01). With both men and women,
platelets from ischemic patients were more aggregable than
were those from normal subjects and from nonischemic
patients (ANOVA: p , 0.01). No difference existed in
aggregability between normal subjects and nonischemic
patients. There was a trend toward greater aggregability in
patients with ACS than in those with stable angina;
Figure 1. Representative tracings for inhibition of ADP (1 mmol/liter)-
induced aggregation by nitroglycerin (NTG) (100 mmol/liter) and sodium
nitroprusside (SNP) (10 mmol/liter) in a whole blood sample obtained
from a normal male subject.
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however, these differences did not reach statistical signifi-
cance.
Inhibition of platelet aggregation by NTG and SNP.
INTERGROUP VARIABILITY. Data from the three groups of
patients examined and from normal subjects are shown in
Figure 2. Inhibition of aggregation by both NTG and SNP
did not vary significantly between normal subjects and
nonischemic patients. Mean inhibition of aggregation by
SNP in platelets from normal subjects was 66 6 19 (SD)%;
hence, responses of ,28% inhibition, corresponding to
.2 SD below normal responsiveness, were treated in multi-
variate analysis as NO resistance (see the following text).
Responses to both NTG and SNP were markedly dimin-
ished in patients with SAP and ACS (ANOVA: p , 0.001
in both groups of patients vs. normals).
UNIVARIATE ANALYSES. Determinants of interindividual
variability in platelet responsiveness to NO were explored in
patients with SAP and with ACS. In view of the similarity
between responses to NTG and SNP in the various patient
groups, only responses to SNP, a more direct NO donor
than NTG (19), were utilized for univariate and multivar-
iate analyses. Results of univariate analysis are presented in
Figure 3. The majority of coronary risk factors and forms of
pharmacotherapy were not associated with significant vari-
ability in SNP responses. However, statin therapy was
associated with significantly increased responses (p 5 0.02),
as was therapy with perhexiline (p , 0.01). Surprisingly,
hypercholesterolemia (p 5 0.04) was also associated with
increased response.
The results of additional analyses did not show any
significant correlation (ANOVA: NS) between number of
risk factors and SNP response. In patients with SAP, no
association was seen between severity of angina (assessed
according to the Canadian Cardiovascular Society classifi-
cation of angina) and NO resistance (ANOVA: NS).
Among patients with ACS, no significant difference existed
in platelet responsiveness to NO donor between patients
with and without myocardial infarction (ANOVA: NS). In
patients with SAP, increasing extent of fixed coronary artery
disease was associated with a nonsignificant (ANOVA: p 5
0.08) trend toward decreased platelet responsiveness.
MULTIVARIATE ANALYSES. Results of multivariate analysis
of factors potentially associated with the presence/absence
of NO resistance are summarized in Table 3. None of the
Table 2. Platelet Aggregation (Ohms) in Response to 1 mmol/liter ADP in Whole Blood From
Normal Subjects, Nonischemic Patients (NIP), Patients With Stable Angina Pectoris (SAP) and
Patients With Acute Coronary Syndromes (ACS)
Subjects Normals NIP SAP ACS
Men 7.7 6 0.7 (23) 7.3 6 0.8 (17) 9.4 6 0.5 (57)* 10.8 6 0.7 (95)**
Women 9.9 6 0.6 (20) 9.5 6 0.6 (18) 13.0 6 0.8 (25)* 13.7 6 0.6 (58)**
Number of subjects indicated in parentheses. *p , 0.05 and **p , 0.01 vs. gender-matched normals.
Figure 2. Inhibition of adenosine diphosphate-induced platelet aggregation by nitroglycerin (NTG) (100 mmol/liter) and sodium nitroprusside (SNP) (10
mmol/liter) in whole blood samples obtained from normal subjects, nonischemic patients (NIP), patients with stable angina pectoris (SAP), and patients
with acute coronary syndromes (ACS). Number of subjects indicated within bars. *p , 0.01 for patients vs. normals and NIP.
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coronary risk factors considered were significant correlates
of response. Both perhexiline and statin therapy remained as
direct correlates of platelet responsiveness to NO, as with
univariate analysis; this suggests that the apparently direct
association of hypercholesterolemia with NO responsive-
ness on univariate analysis reflected the high proportion
(59%) of such patients receiving statins. Importantly, al-
though mean responses to SNP were not significantly
different in SAP and ACS patients (Fig. 2), the presence of
ACS (as distinct from SAP) emerged as a strong correlate of
platelet resistance to NO on multivariate analysis (Table 3).
DISCUSSION
The results of this work provide incremental evidence
linking the phenomenon of NO resistance in platelets with
the presence of symptomatic myocardial ischemia: patients
with SAP or ACS manifest platelet resistance to NO, as
distinct from nonischemic patients, those with chest pain
but normal coronary arteries (Fig. 2). Furthermore, the
diagnosis of ACS, as distinct from SAP, was a determinant
of a worse platelet responsiveness to SNP on multivariate
analysis, with an odds ratio (OR) of 2.3:1 (Table 3). The
presence of NO resistance was independent of conventional
coronary risk factors and the majority of forms of pharma-
cotherapy (Fig. 3). However, on both univariate and mul-
tivariate analyses, both statin therapy and perhexiline ther-
apy were associated with decreased incidence of platelet
resistance to NO.
Ischemia and NO resistance. Although occurring in the
presence of hyperaggregability to ADP (Table 2), NO
resistance is not a consequence of increased platelet aggre-
gation; its biochemical correlate, impaired formation of
cGMP in platelets, occurs in the absence of ADP and is
proportional to impairment of the antiaggregatory effects of
SNP (15). Our results suggest that the extent of symptom-
atic ischemia may contribute to impairment of SNP re-
sponse. One possible mechanism of a correlation between
active ischemia and platelet resistance to NO would be
incremental oxidative stress, engendered at least in part in
association with activation of systemic inflammation, in
particular in patients with ACS (20), as this may lead to
inactivation of platelet guanylate cyclase (21) and acceler-
ated clearance of NO by O2
2 (22), both of which are
implicated as probable causes of NO resistance (16). In view
of these observations, it may have been expected that factors
modifying oxidative stress (presence of SAP and ACS)
might affect responses to NO. The results of comparisons
between ACS or SAP patients and nonischemic patients are
consistent with this supposition. Although the presence (vs.
absence) of creatine kinase elevation was not identified as a
Figure 3. Univariate analyses: interactions of coronary risk factors and pharmacotherapy with inhibition of adenosine diphosphate-induced platelet
aggregation by sodium nitroprusside (10 mmol/liter) in whole blood samples obtained from patients with stable angina pectoris and acute coronary
syndromes. ACE inh 5 angiotensin-converting enzyme inhibitors; ASA 5 aspirin; CaA 5 calcium antagonists; H. Chol 5 high cholesterol; HT 5
hypertension; Pex 5 perhexiline; SH 5 sulphydryl. *p , 0.05. **p , 0.01.
Table 3. Multivariate Analysis: Significant Correlates of
Impaired (,28%) Platelet Response to Sodium Nitroprusside
(10 mmol/liter) in Blood Samples From Patients With Stable
Angina Pectoris (n 5 82) or Acute Coronary Syndromes
(n 5 153)
Variable
Odds
Ratio 95% CI
p
Value
Acute coronary syndromes 2.29 1.18, 4.46 0.012
Perhexiline therapy 0.31 0.11, 0.88 0.018
Statin therapy 0.45 0.22, 0.90 0.021
The following parameters were not significantly correlated with platelet hyporespon-
siveness to sodium nitroprusside: male gender, age .70 years, diabetes mellitus,
systemic hypertension, hypercholesterolemia, smoking, therapy with aspirin, nitrates,
sulphydryl donors (N-acetylcysteine or captopril), angiotensin-converting enzyme
inhibitors, Ca11-antagonists, and beta-adrenoceptor antagonists.
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determinant of NO resistance in the current study, it is
possible that if larger (Q-wave) infarcts were included,
incremental inflammatory activation of neutrophils and
greater redox stress might have resulted in further impair-
ment of NTG and SNP responses. Similarly, it might also
have been expected that conventional coronary risk factors
would be correlated, both individually and cumulatively,
with impaired responsiveness to NO. However, in a recent
study in isolated human internal mammary arteries, only
hyperlipidemia emerged as a significant correlate of vascular
superoxide production (23). Furthermore, our results are
consistent with a recent study (7) that documents no
association between coronary risk factors and responsiveness
to NO donors in the coronary circulation.
Impact of therapy. Platelet resistance to NO should be
distinguished from the phenomenon of acquired nitrate
tolerance, a nitrate-selective attenuation of antiaggregatory
responses that does not affect response to SNP (24). In the
current study, concurrent therapy with prophylactic nitrates
was not associated with abnormal platelet responsiveness to
SNP or to NTG. Although administration of NTG may
inhibit ex vivo platelet aggregation, as we have previously
reported (10), this occurs shortly after NTG intake, in
experiments designed to minimize the impact of a rapid
NTG catabolism (25).
Multivariate analysis revealed (as was suggested on the
basis of univariate analysis) that statin therapy was associ-
ated with augmentation of platelet responsiveness to SNP;
this has not previously been documented. As hypercholes-
terolemia was not a correlate for platelet resistance to NO,
this finding cannot purely represent the cholesterol-
lowering effect of these agents. A potential mechanism
would be limitation of oxidative stress by statin therapy (26).
Furthermore, our finding may provide a theoretical basis for
potential beneficial effects of statins in unstable angina (27).
Therapy with the potent prophylactic antianginal agent
(28,29) perhexiline was associated with augmented platelet
responsiveness to SNP on both univariate and multivariate
analyses, with an OR for elimination of nitrate resistance of
3.2:1. The mechanism of this change might be amelioration
of ischemia (and hence of oxidative stress). A prospective
study has proved that perhexiline therapy normalizes plate-
let responsiveness to NO donors in both SAP and ACS
(30).
The lack of observed correlation between ACE inhibitor
therapy and platelet response to NO may possibly be due to
emergence of such effects only at high doses of ACE
inhibitors (31). It is also important that changes in platelet
responsiveness to NO may not necessarily parallel those of
vascular smooth muscle, despite similarities between our
findings and those of Zeiher’s group (7).
Platelet hyperaggregability (Table 2) combined with hy-
poresponsiveness to exogenous NO donors in patients with
angina (Fig. 2) reflects an impaired physiological response
to endogenous NO (endothelium-derived relaxing factor),
and as such it represents a potential contribution to the
increased risk of ischemic events in such patients. Impair-
ment in responsiveness to NO in ischemic patients implies
a potential problem, namely that those in need of nitrate
therapy may be least likely to respond.
Conclusions. The results of the current study shed new
light on the importance of platelet responsiveness to NO in
angina pectoris. First, it appears that platelet resistance to
NO is a characteristic of patients with severe SAP or ACS.
It is likely that this may contribute both to the pathogenesis
of ischemia in these circumstances and also to the relatively
poor responsiveness to organic nitrates in many of these
patients. Furthermore, impaired responsiveness to NO is
likely to contribute, together with the decreased NO gen-
eration/release from platelets (32), to platelet hyperaggre-
gability in patients with angina pectoris. The finding in the
current study that therapy with statins and with perhexiline
is associated with a lower incidence of platelet resistance to
NO should provide an additional impetus toward investi-
gations of both of these types of agents in the prophylaxis
and treatment of acute and chronic myocardial ischemia.
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